Current Value
$23.421 Year Return
Current Value
$23.421 Year Return
Double maintains 5 strategies that include CPRX - Catalyst Pharmaceuticals, Inc.
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
TAIL | -42.08% | $140.49M | 0.59% |
VIXY | -42.05% | $109.64M | 0.85% |
BTAL | -27.67% | $361.41M | 1.43% |
FXY | -17.36% | $838.61M | 0.4% |
XHLF | -16.20% | $1.46B | 0.03% |
IVOL | -15.33% | $353.94M | 1.02% |
SPTS | -13.80% | $5.76B | 0.03% |
FTSD | -13.67% | $212.46M | 0.25% |
XONE | -13.05% | $603.24M | 0.03% |
FXE | -12.52% | $525.40M | 0.4% |
IBTG | -11.90% | $1.88B | 0.07% |
UDN | -11.25% | $137.74M | 0.78% |
GBIL | -10.88% | $6.17B | 0.12% |
BWX | -9.55% | $1.41B | 0.35% |
BILS | -9.48% | $3.96B | 0.1356% |
TBLL | -8.44% | $2.46B | 0.08% |
UTWO | -8.24% | $387.71M | 0.15% |
SHYM | -7.70% | $322.93M | 0.35% |
VGSH | -7.36% | $22.38B | 0.03% |
BSMW | -7.34% | $102.62M | 0.18% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
K | -12.94% | $28.49B | +32.17% | 2.77% |
VSA | -10.32% | $7.04M | -49.24% | 0.00% |
FUBO | -8.71% | $1.01B | +121.80% | 0.00% |
SYPR | -7.34% | $37.69M | +21.48% | 0.00% |
CODX | -7.11% | $10.29M | -73.23% | 0.00% |
STG | -5.62% | $27.05M | -37.35% | 0.00% |
CIG.C | -5.57% | $2.45B | +9.77% | 0.00% |
FMTO | -5.39% | $45.74M | -99.96% | 0.00% |
AGL | -5.29% | $1.06B | -54.30% | 0.00% |
PSQH | -5.01% | $89.26M | -49.87% | 0.00% |
IRBT | -4.88% | $86.16M | -75.28% | 0.00% |
AQB | -4.64% | $2.96M | -61.58% | 0.00% |
PULM | -4.30% | $23.82M | +239.64% | 0.00% |
RCEL | -3.52% | $158.25M | -19.57% | 0.00% |
CCEC | -2.86% | $1.02B | +3.91% | 2.71% |
SHLS | -2.79% | $765.66M | -33.04% | 0.00% |
HSY | -2.71% | $33.16B | -21.37% | 3.44% |
LTM | -2.41% | $11.01B | -96.75% | 2.75% |
LITB | -2.13% | $21.28M | -72.45% | 0.00% |
ARRY | -2.09% | $1.29B | -25.57% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
PTH | 54.66% | $96.56M | 0.6% |
PBE | 53.78% | $214.12M | 0.58% |
XBI | 53.53% | $4.85B | 0.35% |
XPH | 50.64% | $136.58M | 0.35% |
KJUL | 49.75% | $113.35M | 0.79% |
SMMV | 49.21% | $305.76M | 0.2% |
IBB | 48.53% | $5.22B | 0.45% |
OMFL | 47.90% | $4.75B | 0.29% |
IWO | 47.83% | $11.36B | 0.24% |
PSC | 47.59% | $811.78M | 0.38% |
FTHI | 47.57% | $1.27B | 0.75% |
KJAN | 47.44% | $305.13M | 0.79% |
DUHP | 47.35% | $8.05B | 0.21% |
QUS | 47.34% | $1.49B | 0.15% |
VTWO | 47.33% | $12.07B | 0.07% |
IWM | 47.33% | $63.95B | 0.19% |
XSMO | 47.23% | $1.51B | 0.39% |
PINK | 46.96% | $131.52M | 0.5% |
SMLF | 46.87% | $1.71B | 0.15% |
SLYG | 46.84% | $3.31B | 0.15% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BSSX | 0.29% | $75.11M | 0.18% |
TYA | -0.42% | $149.38M | 0.15% |
IBTO | 0.44% | $330.69M | 0.07% |
LDUR | 0.51% | $849.09M | 0.5% |
CARY | 0.54% | $347.36M | 0.8% |
CLIP | -0.69% | $1.50B | 0.07% |
FTSM | -0.89% | $6.54B | 0.45% |
SPTI | -0.93% | $8.70B | 0.03% |
NYF | 1.00% | $875.13M | 0.25% |
IBTM | -1.07% | $313.33M | 0.07% |
TFLO | -1.10% | $7.06B | 0.15% |
SHM | -1.18% | $3.37B | 0.2% |
CANE | -1.24% | $10.71M | 0.29% |
KCCA | 1.27% | $97.18M | 0.87% |
JMST | 1.31% | $3.65B | 0.18% |
IEF | 1.32% | $34.17B | 0.15% |
UTEN | 1.45% | $192.72M | 0.15% |
IBTL | -1.49% | $367.56M | 0.07% |
SCHR | -1.51% | $10.53B | 0.03% |
SHV | -1.55% | $20.94B | 0.15% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
HROW | 49.44% | $940.24M | +58.54% | 0.00% |
SANA | 48.82% | $385.70M | -80.00% | 0.00% |
AMRX | 48.34% | $2.35B | +11.11% | 0.00% |
VIR | 46.48% | $628.98M | -54.18% | 0.00% |
ACVA | 46.12% | $2.90B | -7.13% | 0.00% |
BSX | 46.04% | $155.14B | +40.66% | 0.00% |
HCAT | 45.34% | $286.06M | -41.54% | 0.00% |
NDAQ | 44.65% | $46.66B | +30.61% | 1.18% |
CRNX | 43.65% | $2.92B | -39.88% | 0.00% |
VCTR | 43.56% | $4.29B | +22.59% | 2.65% |
LGND | 43.52% | $2.00B | +21.70% | 0.00% |
HLNE | 43.43% | $7.37B | +44.47% | 1.15% |
BNT | 43.39% | $11.98B | +33.22% | 0.00% |
GL | 43.20% | $9.95B | +43.64% | 0.82% |
BN | 43.14% | $98.39B | +33.78% | 0.55% |
ACIW | 42.95% | $5.12B | +32.02% | 0.00% |
JXN | 42.13% | $6.09B | +12.55% | 3.41% |
MCO | 42.02% | $87.67B | +18.28% | 0.72% |
PH | 42.00% | $85.95B | +24.68% | 0.99% |
USFD | 41.76% | $17.54B | +38.02% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CIG | 0.01% | $3.47B | -4.10% | 0.00% |
MCK | 0.02% | $88.42B | +27.17% | 0.39% |
MKTX | 0.06% | $8.01B | -1.42% | 1.39% |
IMNN | 0.17% | $8.21M | -59.89% | 0.00% |
KNDI | 0.27% | $106.62M | -44.64% | 0.00% |
DG | -0.35% | $20.45B | -36.56% | 2.55% |
MVO | -0.54% | $66.70M | -38.82% | 21.64% |
FATBB | 0.57% | $50.77M | -11.65% | 9.83% |
LI | 0.58% | $23.85B | +13.34% | 0.00% |
KLG | 0.59% | $1.55B | -16.04% | 3.59% |
CMP | -0.60% | $811.60M | +53.79% | 0.00% |
CBOE | 0.62% | $22.95B | +20.67% | 1.12% |
TKC | 0.69% | $5.49B | -3.37% | 3.28% |
BF.B | -0.78% | $16.82B | -26.93% | 2.49% |
TU | 0.78% | $23.77B | -4.62% | 7.19% |
CPSH | 0.78% | $27.45M | +8.62% | 0.00% |
RILY | -0.78% | $102.47M | -88.22% | 14.71% |
BF.A | -0.81% | $16.72B | -28.57% | 2.51% |
GFI | -0.84% | $18.61B | +31.67% | 2.75% |
AIFU | -0.92% | $9.85M | -95.03% | 0.00% |
Yahoo
Even though Catalyst Pharmaceuticals, Inc.'s ( NASDAQ:CPRX ) recent earnings release was robust, the market didn't seem...
Yahoo
Catalyst Pharmaceuticals Inc (CPRX) reports robust revenue growth and maintains a strong cash position, while addressing potential challenges from generic competition and litigation.
SeekingAlpha
Biotech ETFs face sharp declines, but strong operational momentum in select companies offers investment opportunities.
SeekingAlpha
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ETCompany ParticipantsMichael Kalb - Executive Vice...
Yahoo
The headline numbers for Catalyst (CPRX) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Yahoo
Catalyst (CPRX) delivered earnings and revenue surprises of 28.30% and 8.92%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?